A surprisingly strong GDP report boosted investors' spirits. Plus: American depositary receipts for Novo Nordisk rise after U.S. regulators approved a pill version of weight-loss drug Wegovy. Danny Lewis hosts.
Sign up for the WSJ's free What's News newsletter.
An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor.
Learn more about your ad choices. Visit megaphone.fm/adchoices